Free Trial

Alterity Therapeutics (ATHE) Competitors

$2.00
+0.06 (+3.09%)
(As of 05/24/2024 ET)

ATHE vs. MTEM, NCNA, CMMB, ADXN, GRTX, UPC, AEZS, GHSI, MBRX, and MIRA

Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Molecular Templates (MTEM), NuCana (NCNA), Chemomab Therapeutics (CMMB), Addex Therapeutics (ADXN), Galera Therapeutics (GRTX), Universe Pharmaceuticals (UPC), Aeterna Zentaris (AEZS), Guardion Health Sciences (GHSI), Moleculin Biotech (MBRX), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical preparations" industry.

Alterity Therapeutics vs.

Molecular Templates (NASDAQ:MTEM) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.

Alterity Therapeutics has a net margin of 0.00% compared to Alterity Therapeutics' net margin of -57.92%. Molecular Templates' return on equity of 0.00% beat Alterity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Molecular Templates-57.92% -984.38% -56.85%
Alterity Therapeutics N/A N/A N/A

Molecular Templates has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

95.5% of Molecular Templates shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 18.7% of Molecular Templates shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Molecular Templates received 339 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 67.32% of users gave Molecular Templates an outperform vote while only 60.00% of users gave Alterity Therapeutics an outperform vote.

CompanyUnderperformOutperform
Molecular TemplatesOutperform Votes
342
67.32%
Underperform Votes
166
32.68%
Alterity TherapeuticsOutperform Votes
3
60.00%
Underperform Votes
2
40.00%

Molecular Templates has higher revenue and earnings than Alterity Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Templates$57.31M0.15-$8.12M-$4.32-0.30
Alterity Therapeutics$3.37M2.77-$9.30MN/AN/A

In the previous week, Molecular Templates and Molecular Templates both had 1 articles in the media. Alterity Therapeutics' average media sentiment score of 0.00 equaled Molecular Templates'average media sentiment score.

Company Overall Sentiment
Molecular Templates Neutral
Alterity Therapeutics Neutral

Alterity Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 250.00%. Given Molecular Templates' higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Molecular Templates.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molecular Templates
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Alterity Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Alterity Therapeutics beats Molecular Templates on 7 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATHE vs. The Competition

MetricAlterity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$9.34M$6.69B$5.19B$8.06B
Dividend YieldN/A2.68%2.83%3.93%
P/E RatioN/A14.32131.9416.69
Price / Sales2.77257.352,486.3980.17
Price / CashN/A36.2736.1431.61
Price / Book0.535.775.434.60
Net Income-$9.30M$130.25M$105.99M$213.96M
7 Day PerformanceN/A-2.47%-1.41%-1.11%
1 Month Performance-14.16%1.55%2.68%3.17%
1 Year Performance-25.93%-6.66%3.30%7.82%

Alterity Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTEM
Molecular Templates
2.0252 of 5 stars
$1.49
+6.4%
N/A-81.5%$9.80M$57.31M-0.9662Positive News
Gap Down
NCNA
NuCana
2.9944 of 5 stars
$3.78
+1.3%
$125.00
+3,206.9%
-84.3%$9.86MN/A-0.2425
CMMB
Chemomab Therapeutics
2.379 of 5 stars
$0.88
+8.6%
$5.67
+543.9%
-52.1%$9.72MN/A-0.5520Gap Up
ADXN
Addex Therapeutics
0 of 5 stars
$9.45
+1.3%
N/A-38.3%$10.02M$1.83M-0.5223Gap Up
GRTX
Galera Therapeutics
0 of 5 stars
$0.18
flat
N/A-94.5%$9.57MN/A-0.127News Coverage
UPC
Universe Pharmaceuticals
0 of 5 stars
$2.63
+12.4%
N/A-38.0%$9.50M$32.31M0.00225Gap Up
AEZS
Aeterna Zentaris
2.4959 of 5 stars
$8.40
flat
$60.00
+614.3%
-30.9%$10.16M$4.50M-0.6211Analyst Forecast
News Coverage
High Trading Volume
GHSI
Guardion Health Sciences
0 of 5 stars
$8.55
+3.9%
N/A+34.9%$10.56M$12.25M77.699
MBRX
Moleculin Biotech
1.8472 of 5 stars
$4.85
+3.9%
$35.00
+621.6%
-47.8%$10.80MN/A0.0018Gap Down
MIRA
MIRA Pharmaceuticals
0.8387 of 5 stars
$0.74
+2.8%
N/AN/A$10.91MN/A0.002Gap Down

Related Companies and Tools

This page (NASDAQ:ATHE) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners